Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) Long-Term Debt Issuances (2016 - 2025)

Historic Long-Term Debt Issuances for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q2 2025 value amounting to $2.0 million.

  • Northwest Biotherapeutics' Long-Term Debt Issuances changed N/A to $2.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 2500.0%. This contributed to the annual value of $14.0 million for FY2024, which is 3000.0% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Long-Term Debt Issuances stood at $2.0 million for Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Long-Term Debt Issuances registered a high of $16.1 million during Q4 2021, and its lowest value of $600000.0 during Q1 2022.
  • In the last 5 years, Northwest Biotherapeutics' Long-Term Debt Issuances had a median value of $3.6 million in 2021 and averaged $5.5 million.
  • Its Long-Term Debt Issuances has fluctuated over the past 5 years, first tumbled by 9400.0% in 2022, then surged by 156666.67% in 2023.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Long-Term Debt Issuances stood at $16.1 million in 2021, then plummeted by 68.93% to $5.0 million in 2022, then surged by 100.0% to $10.0 million in 2023, then crashed by 80.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • Its Long-Term Debt Issuances was $2.0 million in Q2 2025, compared to $5.0 million in Q1 2025 and $2.0 million in Q4 2024.